Drug intelligence / Profile preview

levobupivacaine

Development stage
Phase 4
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Infiltration, Nerve Block, Epidural, Intrathecal
01

Overview

Levobupivacaine is a long-acting amino-amide local anesthetic and the single S-enantiomer of bupivacaine. It produces local and regional anesthesia or analgesia by reversibly inhibiting voltage-gated ion channels, principally voltage-gated sodium channels, thereby preventing initiation and propagation of peripheral nerve action potentials. It is administered as a preservative-free solution for infiltration, peripheral nerve block, epidural anesthesia and analgesia, intrathecal anesthesia, and selected ophthalmic blocks. Levobupivacaine has been marketed as **Chirocaine** and has also been evaluated extensively as a regional anesthetic component in perioperative studies, including breast-cancer surgery; these studies concern analgesia rather than direct treatment of cancer. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20997_CHIROCAINE_prntlbl.pdf))

Brand names
Chirocaine
Other names
S-bupivacaineS(-)-bupivacaine(S)-bupivacaine
02

Targets

KCNA5 (Ultra-rapid delayed rectifier potassium channel)KCNH2 (Voltage-gated potassium channel subfamily H member 2)SCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on levobupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levobupivacaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call